Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
This study has been completed.
Study NCT01475461   Information provided by Pfizer

First Received on September 15, 2011.   Last Updated on February 20, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Type 2 Diabetes Mellitus
Additional conditions recognized in this trial
Diabetes Mellitus
Diabetes Mellitus, Type 2
More general conditions related to this trial
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Interventions listed in this trial
Placebo
PF-04937319 - 3mg
PF-04937319 - 20mg
PF-04937319 - 50mg
PF-04937319 - 100mg
Sitagliptin - 100mg
Additional drug interventions recognized in this trial
Sitagliptin
More general drug interventions related to this trial
Dipeptidyl-Peptidase IV Inhibitors
Enzyme Inhibitors
Hypoglycemic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Sponsors listed in this trial
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services